Democrats turn to Nevada, South Carolina after Sanders’ New Hampshire win

By John Whitesides and Amanda Becker

MANCHESTER, N.H. (Reuters) – Democrats vying for the right to challenge U.S. President Donald Trump turned their focus to Nevada and South Carolina after Bernie Sanders solidified his front-runner status with a narrow victory in New Hampshire, with Pete Buttigieg close behind him.

While Sanders, a U.S. senator from neighboring Vermont, and Buttigieg, a former mayor of South Bend, Indiana, finished first and second in Tuesday’s New Hampshire primary respectively, the contest also showed the growing appeal of U.S. Senator Amy Klobuchar of Minnesota, who placed third after surging over the past few days.

Two Democrats whose fortunes have been fading – U.S. Senator Elizabeth Warren of Massachusetts and former Vice President Joe Biden – limped out of New Hampshire, finishing fourth and fifth respectively amid fresh questions about the viability of their candidacies.

New Hampshire was the second contest in the state-by-state battle to pick a Democratic nominee to face Trump, a Republican, in the Nov. 3 election. Sanders and Buttigieg finished in a virtual tie in the first contest last week in Iowa and won an equal number of delegates – who formally vote at the party’s convention in July to select a nominee – in New Hampshire, according to early projections.

The campaign’s focus now begins to shift to states more demographically diverse than the largely white and rural kickoff states of Iowa and New Hampshire. The next contest is on Feb. 22 in Nevada, where more than a quarter of the residents are Latino, followed a week later by South Carolina, where about a fourth are African-American.

After that, 14 states, including California and Texas, vote in the March 3 contests known as Super Tuesday, which will also be the first time voters see the name of billionaire former New York City Mayor Mike Bloomberg on the Democratic presidential ballot.

Democrats must decide whether their best choice to challenge Trump would be a moderate like Buttigieg, Klobuchar, Biden or Bloomberg – or a candidate further to the left like Sanders or Warren.

Only one of the candidates has public events planned on Wednesday. Bloomberg, a billionaire media mogul, plans rallies in Chattanooga and Nashville, Tennessee.

With an eye toward a potential general election campaign against Trump, Bloomberg on Wednesday also announced the opening of a campaign office in New Hampshire headed by Democratic strategist Liz Purdy.

Bloomberg also picked up endorsements from three black members of the U.S. House of Representatives after he came under scrutiny over his past support for a policing tactic known as stop and frisk, which disproportionately affected racial minorities.

In New Hampshire, Sanders had 26% of the vote and Buttigieg had 24%. Klobuchar had 20%, Warren 9% and Biden 8%.

Buttigieg on Wednesday said his strong results in Iowa and New Hampshire showed he had momentum going forward, “settling the questions of whether we could build a campaign across age groups and different kinds of communities.”

Buttigieg, who would be the first openly gay U.S. president if elected, still faces questions about what opinion polls show is his weakness with black voters, one of the most loyal and vital Democratic voting blocs.

‘A WHOLE NEW LOOK’

Asked about how he could gain the confidence of racial minority voters, Buttigieg told MSNBC he was focused on economic empowerment and suggested he had learned lessons, sometimes “the hard way,” as mayor of South Bend. He pointed to a plan he released last summer aimed at fighting racism.

“I think we’re getting a whole new look from black and Latino voters who have so much riding on making sure that we defeat Donald Trump, because they are among those with most to lose if they have to endure yet another term of this president,” he told MSNBC.

In a sign of the growing rivalry between Sanders, 78, and Buttigieg, 38, supporters for the senator booed and chanted “Wall Street Pete!” when Buttigieg’s post-primary speech was shown on screens.

“This victory here is the beginning of the end for Donald Trump,” Sanders told supporters in Manchester, New Hampshire, late on Tuesday.

The Democratic field shrank to nine main candidates after businessman Andrew Yang and U.S. Senator Michael Bennet, who had trailed in the polls and performed poorly on Tuesday, dropped out.

Biden, 77, who was once the front-runner in the Democratic race, stumbled to his second consecutive poor finish after placing fourth in Iowa. He is certain to face growing questions about his ability to consolidate moderate support against a surging Buttigieg and Klobuchar.

Klobuchar’s campaign said it was spending more than $1 million on ads in Nevada.

“We have beaten the odds every step of the way,” Klobuchar, 59, told supporters in Concord. “Because of you, we are taking this campaign to Nevada. We are going to South Carolina. And we are taking this message of unity to the country.”

 

(Reporting by John Whitesides, James Oliphant, Simon Lewis, Michael Martina and Amanda Becker in New Hampshire, additional reporting by Susan Heavey in Washington; Writing by Will Dunham; Editing by Scott Malone, Peter Cooney and Jonathan Oatis)

Buttigieg holds lead over Sanders in latest Iowa caucus results

WASHINGTON (Reuters) – Democratic presidential candidate Pete Buttigieg held his lead over U.S. Senator Bernie Sanders in the Iowa caucuses in updated results released by the Iowa Democratic Party on Wednesday.

Buttigieg, the former mayor of South Bend, Indiana, led with 26.9% of state delegate equivalents, compared to Sanders with 25.2% and U.S. Senator Elizabeth Warren with 18.2%, according to official results with 75% of precincts reporting.

Former U.S. Vice President Joe Biden trailed in fourth place as tabulation of Iowa’s Monday caucus results continued after technology-related delays.

(Reporting by Doina Chiacu; Editing by Tim Ahmann)

Buttigieg leads delegate count in initial Iowa caucus results, Biden in fourth

WASHINGTON (Reuters) – Pete Buttigieg led in Iowa’s initial caucus results with 62% of precincts reporting, with U.S. Senators Bernie Sanders and Elizabeth Warren in second and third place and former Vice President Joe Biden trailing in fourth, the Iowa Democratic Party reported on Tuesday.

Buttigieg had 26.9% of state delegate equivalents, Sanders had 25.1%, Warren had 18.3% and Biden had 15.6%, according to CNN estimates. Tabulation of Iowa’s Monday caucus results continues after technology-related delays.

(Reporting By Amanda Becker; Editing by Chris Reese)

Israeli minister condemns Sanders’ remarks on ‘racist’ Netanyahu government

FILE PHOTO: U.S. 2020 Democratic presidential candidate and Senator Bernie Sanders participates in a moderated discussion at the We the People Summit in Washington, U.S., April 1, 2019. REUTERS/Carlos Barria/File Photo

JERUSALEM (Reuters) – An Israeli cabinet minister condemned U.S. Democratic Party presidential hopeful Bernie Sanders on Tuesday for describing Prime Minister Benjamin Netanyahu’s government as racist over its treatment of Palestinians.

While enjoying unprecedentedly strong backing from the Republican administration of President Donald Trump, some Israelis have been fretting about whether this comes at the cost of losing traditionally bipartisan support in Washington.

Addressing a televised CNN event alongside other Democratic candidates on Monday, Vermont senator Sanders said he was “100 percent pro-Israel” but proposed changing U.S. policy toward it.

“The goal must be to try to bring people together and not just support one country, which is now run by a right-wing, dare I say, racist government,” Sanders said, adding that Netanyahu “is treating the Palestinian people extremely unfairly”.

Netanyahu was reelected to a fifth term on April 9 and appears likely to build a coalition government including religious ultranationalists opposed to Palestinian statehood.

“We condemn statements like that made by Sanders, which was really strange,” Tzachi Hanegbi, a minister in Netanyahu’s outgoing cabinet and senior member of his conservative Likud party, told Israel’s Reshet 13 TV.

“The Israeli government is not a racist government, nor does it include a single racist minister,” the regional cooperation minister said.

“To be right wing is not illegitimate and it is odd that the Democratic Party allows one of its senior members to not respect the democratic choice of the State of Israel.”

Hanegbi cast his own remarks as specific to Sanders rather than any more generalized criticism of the Democratic Party.

Asked whether Israel risked being seen in the United States as a country championed by Republicans, he said: “We make every effort to avoid this danger because, indeed one of Israel’s greatest advantages over all the years was the ability not to get caught up in the political dispute between the parties.”

U.S. Jews overwhelmingly vote Democratic, studies show, a trend that political analysts say has also contributed to a degree of grassroots disconnect between the allies since Trump’s rise. Sanders is himself Jewish and, in his CNN appearance, noted his past visits to, and relatives living in, Israel.

(Writing by Dan Williams; Editing by Alison Williams)

Senator Sanders to ask why drug, once free, now costs $375k

U.S. Senator Bernie Sanders speaks during a news conference on Yemen resolution on Capitol Hill in Washington, U.S., January 30, 2019. REUTERS/Yuri Gripas .

By Yasmeen Abutaleb

WASHINGTON (Reuters) – U.S. Senator Bernie Sanders plans to send a letter to Catalyst Pharmaceuticals on Monday asking it to justify its decision to charge $375,000 annually for a medication that for years has been available to patients for free.

The drug, Firdapse, is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder, according to the letter, made available to Reuters by the senator’s office. The disorder affects about one in 100,000 people in the United States.

The government is intensifying its scrutiny of the pharmaceutical industry and rising prescription drug prices, a top voter concern and a priority of President Donald Trump’s administration.

Both the Democratic-led U.S. House of Representatives and the Senate, controlled by Republicans, have begun holding hearings this year on the rising costs of medicines. Sanders is an independent who usually votes with Democrats.

In the letter dated Feb. 4, Sanders asked Catalyst to lay out the financial and non-financial factors that led the company to set the list price at $375,000, and say how many patients would suffer or die as a result of the price and how much it was paying to purchase or produce the drug.

For years, patients have been able to get Firdapse for free from Jacobus Pharmaceuticals, a small New Jersey-based drug company, which offered it through a U.S. Food and Drug Administration (FDA) program called “compassionate use.”

The program allows patients with rare diseases and conditions access to experimental drugs outside of a clinical trial when there is no viable alternative. 

Florida-based Catalyst received FDA approval of Firdapse in November, along with exclusive rights to market the medication for several years. The company, which bought rights to the drug from a company called BioMarin in 2012, develops and commercializes drugs for rare diseases.

In December, Catalyst announced it would price Firdapse at $375,000 a year. 

“Catalyst’s decision to set the annual list price at $375,000 is not only a blatant fleecing of American taxpayers, but is also an immoral exploitation of patients who need this medication,” Sanders wrote in his letter.

Sanders joins other U.S. lawmakers in investigating the pricing practices of pharmaceutical companies this year.

Democratic Representative Elijah Cummings, chairman of the House Oversight Committee, in January, wrote to 12 pharmaceutical firms asking for detailed information on how they set drug prices. 

Democratic Representatives Frank Pallone and Diana DeGette wrote to the heads of Eli Lilly, Novo Nordisk and Sanofi, the long-time leading manufacturers of insulin, requesting information on why the drug’s price has skyrocketed in recent years.

(Reporting by Yasmeen Abutaleb; Editing by Sonya Hepinstall)